MBBS PhD FRACP FRCPA
Phone: +61 3 9076 3392
Fax: +61 3 9076 2298
- Clinical Haematologist, Alfred Hospital
- Head of Leukaemia Research, Alfred Hospital
- Group Leader, Leukaemia Research Group
- Adjunct Senior Lecturer, Monash University
Andrew Wei is a Victorian Cancer Agency Research Fellow and Haematologist at the Alfred Hospital. He completed his medical training in clinical and laboratory haematology at the University of Melbourne in 2001. He was awarded a Leukaemia Foundation of Australia clinical scholarship whilst at the Walter & Eliza Hall Institute for Medical Research (2002-2005) to study oncogene co-operation in acute leukaemia under the supervision of Professors David Huang and Andrew Roberts. During this time he was awarded the Baikie medal in 2003.
Andrew conducts clinical and translational AML research through dual appointments at the Alfred Hospital and Monash University. He is the chief investigator for national cooperative group clinical studies via the Australasian Leukaemia and Lymphoma Group of which he has been the AML disease group chairperson since 2009. His doctoral studies contributed to discoveries elucidating the functional interaction between pro-apoptotic BH3 and pro-survival Bcl-2 family members (Molecular Cell 2005;17(3):393-403), the importance of Mcl-1 for the BH3 mimetic ABT-737 (Cancer Cell. 2006;10(5):389-99) and the pro-survival function of the EBV Bcl-2 homologue BHRF-1 (PLoS Pathogens 2010;6). Dr Wei is an executive member of the ALLG Scientific Advisory Committee and a member of the National Medical and Scientific Advisory Committee of the Leukaemia Foundation of Australia.
Research Interests and Projects
Dr. Wei’s research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Wei’s laboratory seeks to identify new therapeutic targets in leukaemia.
- Targetting “survival kinases” in leukemic stem and progenitor cells
- The role of inositol phosphatases in regulating normal and malignant hemopoiesis
- Human models of AML
- Phase 1 study of RAD001 + low dose ara-C for older AML
- Phase 1 study of LBH+Azacytidine in older AML
- Phase 1 study of Azacytidine and revlimid as maintenance therapy in AML
- Phase 1 study oh Azacytidine + RAD001 in older AML
- Phase 1 study of Lenalidomide maintenance therapy for adult AML
- Phase 2 study of Randomised control trial of Sorafenib in FLT3-ITD+ AML
- Phase 2 study of HD lenalidomide +/- Azacitidine +/- Depsipeptide in relapsed AML
Current Project Funding
2012 – 2014 NHMRC APP1033248 $543,675 “Dual inhibition of independent cell survival pathways as a new approach for targeting leukaemic stem cells”
2011 – 2013 Leukaemia Foundation Clinical Trial Grant $600,000 Chief Investigator (CIA) “A phase 2 randomized study investigating the FLT3 inhibitor Sorafenib in sequence after intensive chemotherapy for untreated adult AML harbouring FLT3 mutations”.
2011 – 2012 Victorian Cancer Agency Clinical Fellowship $400,000 “Targeting the PI3-kinome for cure in Acute Myeloid Leukaemia”
Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes & Development. 2012;26(2):120-5.
van der Jagt, A., Muirhead, J., Seymour, J., Bradstock, K., Paul, E., and Wei, A. Risk factors for early death after high-dose cytosine arabinoside (HiDAC)- based chemotherapy for adult AML. Leukemia 2011; 26, 362-365
Kvansakul M*, Wei A*, Fletcher J*, Willis S, Chen L, Roberts A, Huang DCS and Colman P. Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. Submitted to Molecular Cell July 2010. *Joint first author.
Wei, A., and Jackson, S. P. (2008). Boosting platelet production. Nature Medicine 14, 917.
Van Delft M*, Wei A*, Chen L, Willis S, Adams J, Huang D. BH3 mimetic ABT-737 induces Bax/Bak-mediated apoptosis, but efficient killing requires Mcl-1 neutralization. Cancer Cell. 2006 Nov;10(5):389-99. *Joint first author.
Chen L*, Willis S*, Wei A*, Hinds M, Colman P, Adams J, Day C, Huang D. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell 2005;17:393 403. *Joint first author.